<DOC>
	<DOCNO>NCT00698776</DOCNO>
	<brief_summary>This single arm open label trial test tolerability combination monocyte derive DCs load KRN7000 ( DC-KRN7000 ) Lenalidomide ( LEN ) patient asymptomatic myeloma . Phase I component study evaluate optimal dose LEN , particular emphasis safety . After interim analysis data , single dose level choose phase II component additional patient .</brief_summary>
	<brief_title>Combination Lenalidomide Autologous Mature Dendritic Cells Pulsed With KRN7000 Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>KRN 7000</mesh_term>
	<criteria>Previously untreated asymptomatic multiple myeloma Prior therapy : Patients receive prior thalidomide , lenalidomide corticosteroid intent treat myeloma . Prior corticosteroid use treatment nonmalignant disorder permit ; concurrent use restrict equivalent prednisone 10 mg per day less . Prior radiation therapy treatment solitary plasmacytoma permit , 3 month elapse last day radiation . Measurable disease define one following : Serum monoclonal protein ≥1.0 g protein electrophoresis &gt; 200 mg monoclonal protein urine 24 hour electrophoresis Measurable soft tissue plasmacytoma . ≥10 % plasma cell measure bone marrow aspirate bone marrow biopsy . Age ≥18 year . ECOG Performance status 0 , 1 , 2 . Willing provide write informed consent . All study participant must register mandatory RevAssistSM program , willing able comply requirement RevAssistSM . Females childbearing potential ( FCBP ) † must negative serum urine pregnancy test sensitivity least 50 mIU/mL 10 14 day prior within 24 hour prescribe lenalidomide ( prescription must fill within 7 day ) must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME , least 4 week start take lenalidomide . FCBP must also agree ongoing pregnancy test . Men must agree father child agree use condom partner child bear potential . See Appendix : Risks Fetal Exposure , Pregnancy Testing Guidelines Acceptable Birth Control Methods . Able take aspirin ( 81 325 mg ) daily prophylactic anticoagulation ( patient intolerant ASA may use warfarin low molecular weight heparin ) . ( b ) Laboratory inclusion criterion obtain ≤ 1 month prior registration : ANC ≥1500/μL PLT ≥100,000/μL Hemoglobin ≥8.0 g/dl Creatinine ≤2.0 mg/dL ( Any elevation normal range felt related myeloma ) Solitary plasmacytoma . Uncontrolled infection . Another active malignancy . Immediate need chemotherapy opinion treat physician . New York Heart Association classification III IV . Existing ≥Grade 2 neuropathy . Any following : Pregnant woman Nursing woman This study involve agent know genotoxic , mutagenic teratogenic effect . Men woman childbearing potential unwilling employ adequate contraception ( condom , diaphragm , birth control pill , injection , intrauterine device [ IUD ] , abstinence , etc . ) Active systemic autoimmunity ( e.g . systemic lupus erythematosus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>